Cargando…
Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease
OBJECTIVE: Identify and characterize circulating metabolite profiles associated with adiposity to inform precision medicine. METHODS: Untargeted plasma metabolomic profiles in the Insulin Resistance Atherosclerosis Family Study (IRASFS) Mexican American cohort (n = 1108) were analyzed for associatio...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640864/ https://www.ncbi.nlm.nih.gov/pubmed/34563731 http://dx.doi.org/10.1016/j.molmet.2021.101342 |
_version_ | 1784609399940055040 |
---|---|
author | Das, Swapan K. Ainsworth, Hannah C. Dimitrov, Latchezar Okut, Hayrettin Comeau, Mary E. Sharma, Neeraj Ng, Maggie C.Y. Norris, Jill M. Chen, Yii-der I. Wagenknecht, Lynne E. Bowden, Donald W. Hsu, Fang-Chi Taylor, Kent D. Langefeld, Carl D. Palmer, Nicholette D. |
author_facet | Das, Swapan K. Ainsworth, Hannah C. Dimitrov, Latchezar Okut, Hayrettin Comeau, Mary E. Sharma, Neeraj Ng, Maggie C.Y. Norris, Jill M. Chen, Yii-der I. Wagenknecht, Lynne E. Bowden, Donald W. Hsu, Fang-Chi Taylor, Kent D. Langefeld, Carl D. Palmer, Nicholette D. |
author_sort | Das, Swapan K. |
collection | PubMed |
description | OBJECTIVE: Identify and characterize circulating metabolite profiles associated with adiposity to inform precision medicine. METHODS: Untargeted plasma metabolomic profiles in the Insulin Resistance Atherosclerosis Family Study (IRASFS) Mexican American cohort (n = 1108) were analyzed for association with anthropometric (body mass index, BMI; waist circumference, WC; waist-to-hip ratio, WHR) and computed tomography measures (visceral adipose tissue, VAT; subcutaneous adipose tissue, SAT; visceral-to-subcutaneous ratio, VSR) of adiposity. Genetic data, inclusive of genome-wide array-based genotyping, whole exome sequencing (WES) and whole genome sequencing (WGS), were evaluated to identify the genetic contributors. Phenotypic and genetic association signals were replicated across ancestries. Transcriptomic data were analyzed to explore the relationship between genetic and metabolomic data. RESULTS: A partially characterized metabolite, tentatively named metabolonic lactone sulfate (X-12063), was consistently associated with BMI, WC, WHR, VAT, and SAT in IRASFS Mexican Americans (P(MA) <2.02 × 10(−27)). Trait associations were replicated in IRASFS African Americans (P(AA) < 1.12 × 10(−07)). Expanded analyses revealed associations with multiple phenotypic measures of cardiometabolic health, e.g. insulin sensitivity (S(I)), triglycerides (TG), diastolic blood pressure (DBP) and plasminogen activator inhibitor-1 (PAI-1) in both ancestries. Metabolonic lactone sulfate levels were heritable (h(2) > 0.47), and a significant genetic signal at the ZSCAN25/CYP3A5 locus (P(MA) = 9.00 × 10(−41), P(AA) = 2.31 × 10(−10)) was observed, highlighting a putative functional variant (rs776746, CYP3A5∗3). Transcriptomic analysis in the African American Genetics of Metabolism and Expression (AAGMEx) cohort supported the association of CYP3A5 with metabolonic lactone sulfate levels (P(FDR) = 6.64 × 10(−07)). CONCLUSIONS: Variant rs776746 is associated with a decrease in the transcript levels of CYP3A5, which in turn is associated with increased metabolonic lactone sulfate levels and poor cardiometabolic health. |
format | Online Article Text |
id | pubmed-8640864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86408642021-12-09 Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease Das, Swapan K. Ainsworth, Hannah C. Dimitrov, Latchezar Okut, Hayrettin Comeau, Mary E. Sharma, Neeraj Ng, Maggie C.Y. Norris, Jill M. Chen, Yii-der I. Wagenknecht, Lynne E. Bowden, Donald W. Hsu, Fang-Chi Taylor, Kent D. Langefeld, Carl D. Palmer, Nicholette D. Mol Metab Original Article OBJECTIVE: Identify and characterize circulating metabolite profiles associated with adiposity to inform precision medicine. METHODS: Untargeted plasma metabolomic profiles in the Insulin Resistance Atherosclerosis Family Study (IRASFS) Mexican American cohort (n = 1108) were analyzed for association with anthropometric (body mass index, BMI; waist circumference, WC; waist-to-hip ratio, WHR) and computed tomography measures (visceral adipose tissue, VAT; subcutaneous adipose tissue, SAT; visceral-to-subcutaneous ratio, VSR) of adiposity. Genetic data, inclusive of genome-wide array-based genotyping, whole exome sequencing (WES) and whole genome sequencing (WGS), were evaluated to identify the genetic contributors. Phenotypic and genetic association signals were replicated across ancestries. Transcriptomic data were analyzed to explore the relationship between genetic and metabolomic data. RESULTS: A partially characterized metabolite, tentatively named metabolonic lactone sulfate (X-12063), was consistently associated with BMI, WC, WHR, VAT, and SAT in IRASFS Mexican Americans (P(MA) <2.02 × 10(−27)). Trait associations were replicated in IRASFS African Americans (P(AA) < 1.12 × 10(−07)). Expanded analyses revealed associations with multiple phenotypic measures of cardiometabolic health, e.g. insulin sensitivity (S(I)), triglycerides (TG), diastolic blood pressure (DBP) and plasminogen activator inhibitor-1 (PAI-1) in both ancestries. Metabolonic lactone sulfate levels were heritable (h(2) > 0.47), and a significant genetic signal at the ZSCAN25/CYP3A5 locus (P(MA) = 9.00 × 10(−41), P(AA) = 2.31 × 10(−10)) was observed, highlighting a putative functional variant (rs776746, CYP3A5∗3). Transcriptomic analysis in the African American Genetics of Metabolism and Expression (AAGMEx) cohort supported the association of CYP3A5 with metabolonic lactone sulfate levels (P(FDR) = 6.64 × 10(−07)). CONCLUSIONS: Variant rs776746 is associated with a decrease in the transcript levels of CYP3A5, which in turn is associated with increased metabolonic lactone sulfate levels and poor cardiometabolic health. Elsevier 2021-09-24 /pmc/articles/PMC8640864/ /pubmed/34563731 http://dx.doi.org/10.1016/j.molmet.2021.101342 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Das, Swapan K. Ainsworth, Hannah C. Dimitrov, Latchezar Okut, Hayrettin Comeau, Mary E. Sharma, Neeraj Ng, Maggie C.Y. Norris, Jill M. Chen, Yii-der I. Wagenknecht, Lynne E. Bowden, Donald W. Hsu, Fang-Chi Taylor, Kent D. Langefeld, Carl D. Palmer, Nicholette D. Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease |
title | Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease |
title_full | Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease |
title_fullStr | Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease |
title_full_unstemmed | Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease |
title_short | Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease |
title_sort | metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640864/ https://www.ncbi.nlm.nih.gov/pubmed/34563731 http://dx.doi.org/10.1016/j.molmet.2021.101342 |
work_keys_str_mv | AT dasswapank metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT ainsworthhannahc metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT dimitrovlatchezar metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT okuthayrettin metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT comeaumarye metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT sharmaneeraj metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT ngmaggiecy metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT norrisjillm metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT chenyiideri metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT wagenknechtlynnee metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT bowdendonaldw metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT hsufangchi metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT taylorkentd metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT langefeldcarld metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease AT palmernicholetted metabolomicarchitectureofobesityimplicatesmetaboloniclactonesulfateincardiometabolicdisease |